- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06349304
Impacto del consumo de uva en polvo en la salud ocular y el estado glucémico en adultos mayores de Singapur
Impacto del consumo regular de uva en la salud ocular y la regulación de los productos finales de glicación avanzada en adultos mayores de Singapur
The purpose of this study is to understand the impacts of regular consumption of freeze-dried table grape powder on eye health and regulation of advanced glycation end products in Singapore older adults. The investigators hypothesize that regular consumption of freeze-dried table grape powder will promote improvements in eye health and lower levels of advanced glycation end products when compared to the placebo group.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
The study will be a 16-week, double-blind, randomized, placebo-controlled trial using a parallel study design. 46 adults (aged 60 - 85) will be recruited and randomly assigned to the intervention or placebo group to investigate whether regular consumption of freeze-dried table grape powder (46g/d) can improve eye health parameters, blood/skin AGE and glycemic status, and reduce inflammation and oxidative stress. This study will consist of 1 screening visit and 5 study visits with 4-week intervals.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Singapore
-
Singapore, Singapore, Singapur, 117550
- National University of Singapore, Faculty of Science, Department of Food Science and Technology
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male and female participants, aged between 60 and 85 years old inclusive
- English-literate and able to give informed consent in English
Exclusion Criteria:
- Smokers
- Allergy to grapes or food dyes/additives, or had serious food allergies in the past
- Known eye diseases (macular degeneration, cataracts, retinopathy or glaucoma), blindness in at least one eye or have had eye surgery
- Unable to view bright lights or flashing lights
- Has Type 1 or 2 diabetes, uremia, cardiovascular disease, abnormal kidney and liver function
- Taking eye medication and/or dietary supplements for the eyes for the past 3 month
- Taking supplements containing carotenoids (e.g. Vitamin A, lutein, zeaxanthin) for past 3 months
- Currently on a specialised diet (e.g. vegetarian, vegan, weight loss diet, low fat diet
- Consumes more than 2 alcoholic drinks per day i.e. one drink is defined as either 150ml of wine,340ml of beer/cider or 45ml of distilled spirit
- Significant change in weight (≥ 3 kg body weight) in the past 3 months
- Significant exercise pattern over the past 3 months defined as high-intensity exercise of more than 3 hours per week
- Currently on anti-hypertensive, cholesterol-lowering or psychoactive drugs
- Scored ≤ 7 on the abbreviated mental test
- Poor peripheral venous access based on past experiences with blood draw
- Participating in another clinical study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Freeze-dried table grape powder
Subjects in this group will be given pouches, each containing 46 g of freeze-dried table grape powder, with an instruction sheet on how to prepare the powder into a drink for consumption.They will consume one pouch a day. |
Consumption of grape powder as part of daily diet |
|
Comparador de placebos: Placebo table grape powder
Subjects in this group will be given pouches, each containing 46 g of placebo grape powder, with an instruction sheet on how to prepare the powder into a drink for consumption.They will consume one pouch a day. |
Consumption of placebo grape powder as part of daily diet |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Macular pigment optical density
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16
|
A measurement of macular pigment of the eye using a heterochromatic flicker photometry device. The measurements are in arbitrary units. |
Week 0, Week 4, Week 8, Week 12, Week 16
|
|
Visual acuity
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16
|
Participants will read out letters on a ETDRS LogMAR chart at a fixed distance where letters becomes smaller as it goes down the chart. Tests results will be recorded in number of letters read, where the more letters the better the outcome. |
Week 0, Week 4, Week 8, Week 12, Week 16
|
|
Photostress recovery time
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16
|
An ophthalmoscope will be used to shine a light into the participants eye for 10 seconds, and participants will be required to read letters off a chart the moment their vision returns to normal. The faster the recovery time, the better the outcome. Units will be in seconds |
Week 0, Week 4, Week 8, Week 12, Week 16
|
|
Visual function questionnaire 25
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16
|
A questionnaire to for participants to self-evaluate their perception of their current eye health based on general vision, ocular pain, near activities, distance activities, vision specific functions, driving, color vision and peripheral vision. The best possible score is 100 and worst possible score is 0. |
Week 0, Week 4, Week 8, Week 12, Week 16
|
|
Skin advanced glycation end products levels
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16
|
Measurement of skin advanced glycation end products level using a skin autofluorescence device, where participants wlll be instructed to place their forearm over the device and a light will be shone and a reading can be captured by detecting fluorescence. The results will be presented as arbitrary units. |
Week 0, Week 4, Week 8, Week 12, Week 16
|
|
Dietary advanced glycation end products level
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16
|
Participants will be instructed to record down 3-day food records, from Thursday to Saturday, before each clinical visit. This will be used to estimate their advanced glycation end products intake from food by referring to existing nutrient databases. Units will be based on a common advanced glycation end product measured, carboxymethyllysine (CML), thus the unit will be mg CML/ kg food |
Week 0, Week 4, Week 8, Week 12, Week 16
|
|
Blood advanced glycation end products levels
Periodo de tiempo: Week 0, Week 8 and Week 16
|
Participants will have their blood drawn by medical professionals at the Occupational Health Clinic. The blood will be processed and stored. Measurements will be done using ultra-performance liquid chromatography coupled with mass spectrometry techniques to determine the levels of advanced glycation end products. Units will be in μg/mL. |
Week 0, Week 8 and Week 16
|
|
Contrast sensitivity
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16
|
Participants will read out letters on a ETDRS LogMAR chart at a fixed distance, where the letters differs in lightness to test participants' sensitivity to contrast. Tests results will be recorded in number of letters read, where the more letters the better the outcome. |
Week 0, Week 4, Week 8, Week 12, Week 16
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Concentration of tumour necrosis factor-α
Periodo de tiempo: Week 0, Week 8, Week 16
|
The blood obtained from the participants will be processed for storage. Tumor necrosis factor-α results will be presented in ng/L according to the commercially available enzyme-linked immunosorbent assay kits. |
Week 0, Week 8, Week 16
|
|
Concentration of interleukin-6
Periodo de tiempo: Week 0, Week 8, Week 16
|
The blood obtained from the participants will be processed for storage. Interleukin-6 results will be presented in ng/L according to the commercially available enzyme-linked immunosorbent assay kits. |
Week 0, Week 8, Week 16
|
|
Concentration of high-sensitivity C-reactive protein
Periodo de tiempo: Week 0, Week 8, Week 16
|
The blood obtained from the participants will be processed for storage. Analyses of inflammation markers include tumor necrosis factor-α, interleukin-6. high sensitivity C-reactive protein. Tumor necrosis factor-α and interleukin-6 results will be presented in ng/L according to the commercially available enzyme-linked immunosorbent assay kits. High-sensitivity C-reactive protein results will be obtained and presented in mg/L by commercial lab testing. |
Week 0, Week 8, Week 16
|
|
Concentration of fasting blood glucose
Periodo de tiempo: Week 0, Week 8, Week 16
|
Fasting blood glucose will be measured using commercial lab testing using participants' blood, units will be in mmol/L. |
Week 0, Week 8, Week 16
|
|
Concentration of malondialdehyde
Periodo de tiempo: Week 0, Week 8, Week 16
|
The blood obtained from the participants will be processed for storage. Analyses of malondialdehyde using commercially available enzyme-linked immunosorbent assay kits. Units for malondialdehyde will be in ng/L according to assay kit instructions. |
Week 0, Week 8, Week 16
|
|
Concentration of 8-isoprostaglandin-F2α
Periodo de tiempo: Week 0, Week 8, Week 16
|
The blood obtained from the participants will be processed for storage. Analyses of 8-isoprostaglandin-F2α using commercially available enzyme-linked immunosorbent assay kits. Units for 8-isoprostaglandin-F2α will be in µmol/L according to assay kit instructions. |
Week 0, Week 8, Week 16
|
|
Skin carotenoid status
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16;
|
Measured using a commercially available device that measured carotenoids using Raman spectroscopy. Results are in arbitrary units. |
Week 0, Week 4, Week 8, Week 12, Week 16;
|
|
Concentration of insulin
Periodo de tiempo: Week 0, Week 8, Week 16
|
Fasting blood insulin will be measured using commercial lab testing using participants' blood, units in μU/L. |
Week 0, Week 8, Week 16
|
|
Percentage of glycated hemoglobin
Periodo de tiempo: Week 0, Week 8, Week 16
|
Glycated hemoglobin will be measured using commercial lab testing from participant's blood, units in percent. |
Week 0, Week 8, Week 16
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Measurement of height
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16
|
Height will be measured using height-weight scale and units will be in cm. |
Week 0, Week 4, Week 8, Week 12, Week 16
|
|
Measurement of blood pressure
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16
|
A blood pressure monitoring device available commercially will be used be to measure their systolic nad diastolic blood pressure. |
Week 0, Week 4, Week 8, Week 12, Week 16
|
|
Measurement of weight
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16
|
Weight will be measured using height-weight scale and units will be in kg. |
Week 0, Week 4, Week 8, Week 12, Week 16
|
|
Measurement of waist circumference
Periodo de tiempo: Week 0, Week 4, Week 8, Week 12, Week 16
|
Waist circumference will be measured using a measuring tape by a trained personnel, units in cm. |
Week 0, Week 4, Week 8, Week 12, Week 16
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jung Eun Kim, Ph.D., R.D., National University of Singapore
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- S25
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Electronic copies of the data with identifiable participant information will be kept on NUS OneDrive with access limited only Dr Kim Jung Eun and her research staff. All data will be de-identified prior to statistical analyses.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .